Jeffrey T. L. Smith
EVP & Chief Medical Officer · Zymeworks Inc.
- 2026
- Jan 13, 2026
- 2
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Jeffrey T. L. Smith files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Kenneth Galbraith - $3.34M in ZYME purchases and sales in the last 12 months
- Paul Andrew Moore - $721K in ZYME purchases and sales in the last 12 months
- Adam Schayowitz - $358K in ZYME purchases and sales in the last 12 months
- Mark Hollywood - $139K in ZYME purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Jeffrey T. L. Smith?
Jeffrey T. L. Smith is a corporate insider, tracked as EVP & Chief Medical Officer of Zymeworks Inc. (ZYME). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Jeffrey T. L. Smith last file a Form 4?
The most recent primary Form 4 on record is dated 13 January 2026, one of 2 filings going back to 2026.
Has Jeffrey T. L. Smith been buying or selling stock?
Recorded transactions: 0 open-market purchases and 2 open-market sales ($476K) across all tracked filings.
